Literature DB >> 22966992

Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

Y Yilmaz1.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is currently conceptualised as a clinical spectrum that results from a ‘multiple-hit’ process which begins with simple steatosis and subsequently renders the hepatocytes susceptible to a variety of insults. Ultimately, more serious liver injuries like non-alcoholic steatohepatitis (NASH) and cirrhosis may develop. Although the metabolic syndrome is considered the crucial player in the pathogenesis of NAFLD, recent studies have highlighted novel pathophysiological mechanisms in this clinical entity. AIM: To discuss the pathophysiology of NAFLD based on the hypothesis that simple steatosis and NASH are discrete entities rather than two points on a spectrum.
METHODS: A literature search was conducted in August 2012 on PubMed, Ovid Embase, Ovid Medline and Scopus using the following search terms: steatosis, non-alcoholic steatohepatitis, pathophysiology, fatty liver, natural history and genetics.
RESULTS: Simple steatosis and NASH appear as two distinct pathophysiological entities and progression from pure fatty liver to NASH appears to be so rare as to warrant publication. The possible pathogenetic pathways specifically related to NASH are highlighted.
CONCLUSIONS: Although simple steatosis and non-alcoholic steatohepatitis are currently viewed as two histological subtypes of the unique spectrum of non-alcoholic fatty liver disease, the two conditions are likely distinct not only from a histological but also from a pathophysiological standpoint. Efforts to distinguish simple steatosis from non-alcoholic steatohepatitis using non-invasive modalities should be informed by the current pathophysiology of these two clinical entities.

Entities:  

Mesh:

Year:  2012        PMID: 22966992     DOI: 10.1111/apt.12046

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  75 in total

1.  Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors:  Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal:  Intern Emerg Med       Date:  2015-11-24       Impact factor: 3.397

2.  Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats.

Authors:  Zheng Yao; Xiao-Chen Liu; Ying-Er Gu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

3.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

4.  CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Authors:  Sila Cocciolillo; Giustino Parruti; Leonardo Marzio
Journal:  World J Hepatol       Date:  2014-07-27

Review 5.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

6.  Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Iradj Maleki; Mahmood Reza Aminafshari; Tarang Taghvaei; Vahid Hosseini; Alireza Rafiei; Zhila Torabizadeh; Maryam Barzin; Elahe Orang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 7.  Epidemiology of fatty liver: an update.

Authors:  Giorgio Bedogni; Valerio Nobili; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

Review 9.  Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease.

Authors:  Mustafa Koplay; Mesut Sivri; Hasan Erdogan; Alaaddin Nayman
Journal:  World J Hepatol       Date:  2015-04-18

Review 10.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.